Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 Levels in Male Patients With Hypogonadism
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 92
- 试验地点
- 1
- 主要终点
- Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 levels
研究概览
简要总结
The aim of this study is to investigate the markers of bone mineral metabolism in an unconfounded group of patients with hypogonadism and to search for a relationship between endothelial dysfunction and insulin resistance.
详细描述
Cardiometabolic disorders are prevalent in patients with hypogonadism. Endothelial dysfunction and insulin resistance are used in determining cardiovascular risk. The role of markers of bone mineral metabolism in hypogonadism is not clearly presented.
49 male patients with hypogonadotropic hypogonadism (HH) and 43 BMI and age matched healthy male subjects were enrolled. Osteoprotegerin (OPG), fibroblast growth factor-23 (FGF-23), vitamin D and asymmetric dimethylarginine (ADMA) levels were measured. The insulin sensitivity was estimated by homeostatic model assessment-insulin resistance (HOMA-IR) formula.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •male patients with hypogonadotropic hypogonadism
- •being under the age of 45 and over the age of 18
- •not previously given testosterone or human chorionic gonadotropin therapy
- •not have any chronic metabolic disorders or organ dysfunction
排除标准
- •female patients
- •Other reasons hipogondism
- •receive any treatment of hypogonadism
- •presence of comorbid diseases
结局指标
主要结局
Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 levels
时间窗: one year
investigate the markers of bone mineral metabolism in patients with hypogonadism
次要结局
- relationship between bone mineral metabolism and endothelial dysfunction, insulin resistance(one year)
研究者
Coskun Meric
MD
Gulhane School of Medicine